Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis

作者全名："Bai, Jie; Yao, Xufeng; Pu, Yinghong; Wang, Xiaoyi; Luo, Xinrong"

作者地址："[Bai, Jie; Yao, Xufeng; Pu, Yinghong; Wang, Xiaoyi; Luo, Xinrong] Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing, Peoples R China; [Yao, Xufeng] First Hosp Jiaxing, Dept Head & Neck Surg, Jiaxing, Zhejiang, Peoples R China"

通信作者："Wang, XY; Luo, XR (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing, Peoples R China."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001102274200001

JCR分区：Q2

影响因子：3.5

年份：2023

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：capecitabine; triple-negative breast cancer; chemotherapy; survival; adverse events

摘要："Introduction: The efficacy and safety of adjuvant capecitabine in early-stage triple-negative breast cancer remains undefined. A meta-analysis was conducted to elucidate whether capecitabine-based regimens could improve survival in early-stage triple-negative breast cancer (TNBC).Methods: The current study searched Medline, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov proceedings up to 2023.9. Disease-free survival (DFS), overall survival (OS), and grade 3-4 adverse events (AEs) were assessed. Extracted or calculated hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled.Results: The capecitabine-based regimens showed significant advantages in DFS (HR = 0.81, 95% CI: 0.73-0.90; P <.001) and OS (HR = 0.75, 95% CI: 0.65-0.87; P <.001) from 12 randomized controlled trials (RCTs) with 5,390 unselected participants. Subgroup analysis of DFS showed analogous results derived from patients with lymph node negative (HR = 0.68, 95% CI: 0.50-0.92; P = .006) and capecitabine duration no less than six cycles (HR = 0.73; 95% CI: 0.62-0.86; P <.001). Improvement of DFS in the addition group (HR = 0.77, 95% CI: 0.68-0.87; P <.001) and adjuvant setting (HR = 0.79, 95% CI: 0.70-0.89; P <.001) was observed. As to safety profile, capecitabine was associated with more frequent stomatitis (OR = 5.05, 95% CI: 1.45-17.65, P = .011), diarrhea (OR = 6.11, 95% CI: 2.12-17.56; P =.001), and hand-foot syndrome (OR = 31.82, 95% CI: 3.23-313.65, P = .003).Conclusions: Adjuvant capecitabine-based chemotherapy provided superior DFS and OS to early-stage TNBC. The benefits to DFS in selected patients with lymph node negative and the addition and extended duration of capecitabine were demonstrated."

基金机构：This work was supported by the National Natural Science Foundation of China (no. 82003135) and the Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0147). [82003135]; National Natural Science Foundation of China [cstc2021jcyj-msxmX0147]; Natural Science Foundation of Chongqing

基金资助正文：This work was supported by the National Natural Science Foundation of China (no. 82003135) and the Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0147).